1. Gilead Sciences Projects $107 Million Q1 Earnings Hit from R&D Deal Spree
Gilead Sciences has flagged a significant $107 million headwind to its first-quarter earnings, a direct consequence of its recent push into external research and development partnerships. This upfront financial impact, disclosed by the biopharmaceutical giant, signals the immediate cost of its strategy to bolster its p...